Tackling Common Problems in Tableting and Tooling - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tackling Common Problems in Tableting and Tooling
The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.


Pharmaceutical Technology
pp. s22-s25

Anti-stick research

PharmTech: Could you tell us more about the TSAR project, for which you are collaborating with the University of Nottingham?

I Holland: Since the launch of our PharmaCote range of punch and die coatings more than five years ago, I Holland has been increasingly called on to solve sticking issues within the pharmaceutical sector as tablet manufacturers realize that these problems can be eliminated without reducing product yield and investing in expensive magnesium stearate systems. The traditional way of troubleshooting a sticking problem would have been to supply a customer with a test set of tools containing many different punch and die coatings. A full compression trial would be carried out at the customer's site to ascertain the coating that would most effectively solve the sticking problem. This approach involves a significant investment for the customer in the tooling as well as in time.

The aim of the TSAR project is to develop a predictive tool that will allow us to identify which punch and die coating is most likely to solve these sticking issues, thus removing the need to carry out full-scale compression trials with all of the anti-stick coatings. The development of the predictive tool will not commence until we have gathered sufficient interaction data from many different excipients and active ingredients. This work is currently in progress as we are testing several samples supplied by our customers.

We aim to use newly developed multivariant analysis techniques linked to nanoscale surface chemistry and morphology techniques such as atomic force microscopy (AFM), time-of-flight secondary ion mass spectroscopy (ToFSIMS), Raman spectroscopy, contact angle measurements, X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM), and laser profilometry. Once the data are gathered, we will use a principle component analysis tool to allow us to group the different excipients/active ingredients. Only after this process, will we be able to start the development of the predictive tool.

We are currently halfway through the two-year project and have spent the first year solely gathering data from various products supplied to us by different customers. The most utilized piece of equipment to date has been the AFM, which allows us to quantitatively map, at the nanoscale, adhesion on PharmaCote coated tablet punches using single drug/excipient particles. The low adhesion force measurements (nN) gathered within the AFM indicates the level of Van der Waals forces that are present. We are also changing the humidity and temperature within the testing environment to gather data on capillary forces that are present. Only when all the ingredients of the formulation are tested in this analytical way, do we move the formulation into a production environment and compress tablets using the same PharmaCote coated tooling.

This 'real world' checking allows the results of the analytical testing to be verified in a production environment and gives the customer the reassurance that they are purchasing the optimum solution for their specific problem. It cannot be stressed enough how each sticking problem is unique and can vary significantly from site to site, press to press, and product to product, which makes laboratory compression testing vital.

References

1. Eurostandard Educational Collection 2010 Edition.

2. T. Higgins, Pharm. Tech. 37 (2) 30–31 (2013).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here